Medexus Pharmaceuticals (MDP) Aandelenoverzicht
Medexus Pharmaceuticals Inc. is actief als farmaceutisch bedrijf in Canada en de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor MDP uit onze risicocontroles.
MDP Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medexus Pharmaceuticals Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | CA$5.14 |
| 52 Week Hoogtepunt | CA$5.23 |
| 52 Week Laag | CA$2.47 |
| Bèta | 1.81 |
| 1 maand verandering | 30.13% |
| 3 maanden verandering | 46.86% |
| 1 Jaar Verandering | 65.27% |
| 3 jaar verandering | 167.71% |
| 5 jaar verandering | -30.54% |
| Verandering sinds IPO | -31.47% |
Recent nieuws en updates
Narratiefupdate • Jun 17
MDP: Share Repurchases And New Cell Therapy Rights Will Support Upside
Analysts have modestly adjusted their fair value price target for Medexus Pharmaceuticals stock to CA$8.00, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations, while keeping the overall valuation level unchanged. What's in the News for Medexus Pharmaceuticals Secured exclusive Canadian rights to commercialize UM171 Cell Therapy, branded as Zemcelpro (dorocubicel) in Europe, through a license and supply agreement with ExCellThera and its subsidiary Cordex Biologics.Narratiefupdate • Jun 02
MDP: Ongoing Share Repurchases Will Support Upside Potential
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E as the key drivers of the revised valuation. What's in the News Medexus reported an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, with 56 healthcare institutions having granted positive formulary inclusion decisions as of March 31, 2026, and 64 transplant centers having ordered the product for procedures.Narratiefupdate • Apr 27
MDP: Share Repurchases And Transplant Center Adoption Will Support Upside
Analysts have modestly raised their CA$ price target on Medexus Pharmaceuticals, citing slightly higher modeled revenue growth of 21.21% and a profit margin assumption of 24.84%, while keeping the fair value and discount rate unchanged. What's in the News Medexus provided an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, including recent progress with transplant center formulary decisions and ordering activity.Recent updates
Narratiefupdate • Jun 17
MDP: Share Repurchases And New Cell Therapy Rights Will Support Upside
Analysts have modestly adjusted their fair value price target for Medexus Pharmaceuticals stock to CA$8.00, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations, while keeping the overall valuation level unchanged. What's in the News for Medexus Pharmaceuticals Secured exclusive Canadian rights to commercialize UM171 Cell Therapy, branded as Zemcelpro (dorocubicel) in Europe, through a license and supply agreement with ExCellThera and its subsidiary Cordex Biologics.Narratiefupdate • Jun 02
MDP: Ongoing Share Repurchases Will Support Upside Potential
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E as the key drivers of the revised valuation. What's in the News Medexus reported an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, with 56 healthcare institutions having granted positive formulary inclusion decisions as of March 31, 2026, and 64 transplant centers having ordered the product for procedures.Narratiefupdate • Apr 27
MDP: Share Repurchases And Transplant Center Adoption Will Support Upside
Analysts have modestly raised their CA$ price target on Medexus Pharmaceuticals, citing slightly higher modeled revenue growth of 21.21% and a profit margin assumption of 24.84%, while keeping the fair value and discount rate unchanged. What's in the News Medexus provided an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, including recent progress with transplant center formulary decisions and ordering activity.Narratiefupdate • Apr 09
MDP: Share Buyback And Higher Future P E Multiple Will Support Upside
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth, profit margins, and future P/E that refine their outlook on the company’s valuation. What's in the News Medexus Pharmaceuticals completed a share buyback tranche covering 191,900 shares, equal to 0.59% of its shares, between November 20, 2025 and December 31, 2025 (Key Developments).Narratiefupdate • Mar 26
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have modestly lifted their price target on Medexus Pharmaceuticals to CA$8.00, reflecting slightly higher modeled revenue growth, a small uptick in profit margin assumptions, and a marginally lower future P/E multiple. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares from November 20, 2025 to December 31, 2025, representing 0.59% of its shares, for a total of CA$0.52 million under its previously announced buyback program (Key Developments).Narratiefupdate • Mar 11
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have raised their CA$ price target on Medexus Pharmaceuticals, citing slightly stronger modeled revenue growth of 19.57% and a profit margin of 27.71%, along with a modestly lower forward P/E of 4.80x in their updated assumptions. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of shares, for CAD 0.52 million under its buyback program announced on November 20, 2025 (Key Developments).Narratiefupdate • Feb 25
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have revised their CA$ price target on Medexus Pharmaceuticals upward, reflecting updated assumptions that include modeled revenue growth of 19.35%, a profit margin of 27.36% and a slightly lower forward P/E of 4.85x. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of its outstanding equity, for a total cost of CA$0.52 million under the buyback announced on November 20, 2025 (Key Developments).Narratiefupdate • Feb 10
MDP: Share Repurchase Plan Will Support Higher Future Shareholder Value
Analysts have modestly adjusted their price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth of about 17.94%, profit margin of about 25.99% and a future P/E of about 5.10x. Together, these figures inform a refreshed fair value view of US$8.00 per share.Narratiefupdate • Jan 26
MDP: Share Repurchase Plan Will Support Stronger Future Shareholder Returns
Analysts have lifted their price target on Medexus Pharmaceuticals to US$8.00 from US$8.00, citing slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a small adjustment to the future P/E assumption. What's in the News Medexus Pharmaceuticals has announced a share repurchase program that allows the company to buy back up to 2,983,650 shares, or 9.2% of its issued share capital, with all repurchased shares set to be cancelled.Narratiefupdate • Jan 11
MDP: Share Repurchase Program Will Support Stronger Future Shareholder Returns
Analysts have reaffirmed their price target on Medexus Pharmaceuticals at US$8.00, citing updated assumptions for revenue growth, profit margins, and future P/E that adjust their overall outlook while keeping the fair value level unchanged. What's in the News Medexus Pharmaceuticals Inc.Analyseartikel • Jan 03
Does Medexus Pharmaceuticals (TSE:MDP) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narratiefupdate • Dec 16
MDP: Share Repurchase Program Will Drive Stronger Future Shareholder Returns
Analysts have raised their price target for Medexus Pharmaceuticals to approximately $8.00 per share from about $6.00, citing expectations of stronger revenue growth, a substantial improvement in profit margins, and a lower projected future P/E multiple that enhances the stock's valuation appeal. What's in the News Medexus Pharmaceuticals Inc.
Narratiefupdate • Aug 20
US Transplant Centers Will Drive Specialty Care Adoption
Despite notable improvements in net profit margin and revenue growth forecasts, the consensus analyst price target for Medexus Pharmaceuticals has been revised downward from CA$7.11 to CA$6.71. What's in the News Medexus Pharmaceuticals received approval from US CMS for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX™ (treosulfan) for Injection for fiscal year 2026.Narratiefupdate • Aug 06
US Transplant Centers Will Drive Specialty Care Adoption
The notable increase in Medexus Pharmaceuticals' consensus price target is primarily driven by a significant rise in its future P/E valuation, with fair value revised upward from CA$6.50 to CA$7.11. Valuation Changes Summary of Valuation Changes for Medexus Pharmaceuticals The Consensus Analyst Price Target has risen from CA$6.50 to CA$7.11.Analyseartikel • May 04
Earnings Tell The Story For Medexus Pharmaceuticals Inc. (TSE:MDP) As Its Stock Soars 28%
Those holding Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares would be relieved that the share price has rebounded 28...
Nieuw narratief • Feb 19
FDA Approval Of GRAFAPEX Will Unlock Market Potential With 7 Years Exclusivity
Successful FDA approval for GRAFAPEX is expected to significantly increase revenue, providing a robust new stream with its granted exclusivity.Analyseartikel • Jan 19
Investors Appear Satisfied With Medexus Pharmaceuticals Inc.'s (TSE:MDP) Prospects As Shares Rocket 52%
Despite an already strong run, Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have been powering on, with a gain of...Analyseartikel • Dec 05
After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 31% after a shaky period...Analyseartikel • Nov 05
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Medexus Pharmaceuticals Inc.'s ( TSE:MDP ) stock was strong despite it releasing a soft earnings report last week. We...Analyseartikel • Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Medexus Pharmaceuticals Inc. ( TSE:MDP ) just released its latest quarterly results and things are looking bullish. It...Analyseartikel • Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shareholders have had their patience rewarded with a 29% share price jump in...Analyseartikel • Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Analyseartikel • Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
The Medexus Pharmaceuticals Inc. ( TSE:MDP ) share price has softened a substantial 26% over the previous 30 days...Analyseartikel • Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 89% after a shaky period...Analyseartikel • Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Rendement voor aandeelhouders
| MDP | CA Pharmaceuticals | CA Markt | |
|---|---|---|---|
| 7D | 22.4% | 2.8% | 1.0% |
| 1Y | 65.3% | 53.0% | 29.6% |
Rendement versus industrie: MDP overtrof de Canadian Pharmaceuticals industrie, die het afgelopen jaar een rendement 53 % opleverde.
Rendement versus markt: MDP overtrof de Canadian markt, die het afgelopen jaar een rendement opleverde van 29.6 %.
Prijsvolatiliteit
| MDP volatility | |
|---|---|
| MDP Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in CA Market | 16.7% |
| 10% least volatile stocks in CA Market | 3.7% |
Stabiele aandelenkoers: MDP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Canadian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van MDP is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2000 | 90 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. is een farmaceutisch bedrijf in Canada en de Verenigde Staten. Het bedrijf richt zich op de therapeutische gebieden oncologie, hematologie, reumatologie, auto-immuunziekten, allergie en dermatologie. De belangrijkste producten van het bedrijf zijn IXINITY, een intraveneus recombinant factor IX-therapeuticum voor gebruik bij patiënten met hemofilie B; Rasuvo en Metoject, een formulering van methotrexaat voor de behandeling van reumatoïde artritis en andere auto-immuunziekten; Rupall, een receptplichtig geneesmiddel tegen allergie; en Gleolan, een optisch beeldvormingsmiddel dat wordt gebruikt bij patiënten met glioom als hulpmiddel voor de visualisatie van kwaadaardig weefsel tijdens chirurgie.
Medexus Pharmaceuticals Inc. Samenvatting
| MDP fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | CA$165.58m |
| Inkomsten(TTM) | -CA$3.40m |
| Inkomsten(TTM) | CA$141.07m |
1.2x
P/S-verhouding-47.9x
Koers/WinstverhoudingIs MDP overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MDP resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$99.33m |
| Kosten van inkomsten | US$35.48m |
| Brutowinst | US$63.86m |
| Overige uitgaven | US$66.25m |
| Inkomsten | -US$2.39m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.076 |
| Brutomarge | 64.29% |
| Nettowinstmarge | -2.41% |
| Schuld/Eigen Vermogen Verhouding | 44.9% |
Hoe presteerde MDP op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/03 05:02 |
| Aandelenkoers aan het einde van de dag | 2026/07/03 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Medexus Pharmaceuticals Inc. wordt gevolgd door 10 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Scott Henry | Alliance Global Partners |
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |